1. Azabenzthiazole inhibitors of leukotriene A₄ hydrolase.
- Author
-
Tanis VM, Bacani GM, Blevitt JM, Chrovian CC, Crawford S, De Leon A, Fourie AM, Gomez L, Grice CA, Herman K, Kearney AM, Landry-Bayle AM, Lee-Dutra A, Nelson J, Riley JP, Santillán A Jr, Wiener JJ, Xue X, and Young AL
- Subjects
- Animals, Aza Compounds chemical synthesis, Aza Compounds chemistry, Benzothiazoles chemical synthesis, Benzothiazoles chemistry, Dose-Response Relationship, Drug, Drug Design, Enzyme Inhibitors chemical synthesis, Enzyme Inhibitors chemistry, Epoxide Hydrolases metabolism, Ether-A-Go-Go Potassium Channels antagonists & inhibitors, Humans, Mice, Molecular Structure, Structure-Activity Relationship, Aza Compounds pharmacology, Benzothiazoles pharmacology, Enzyme Inhibitors pharmacology, Epoxide Hydrolases antagonists & inhibitors
- Abstract
Previously, benzthiazole containing LTA(4)H inhibitors were discovered that were potent (1-3), but were associated with the potential for a hERG liability. Utilizing medicinal chemistry first principles (e.g., introducing rigidity, lowering cLogD) a new benzthiazole series was designed, congeners of 1-3, which led to compounds 7a, 7c, 12a-d which exhibited LTA(4)H IC(50)=3-6 nM and hERG Dofetilide Binding IC(50)=8.9-> >10 μM., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF